Samsung Biologics CEO John Rim Reports Strong Q3 2025 Results, Reinforcing Global CDMO Leadership

Samsung Biologics, a leading global contract development and manufacturing organization (CDMO), has announced impressive third-quarter 2025 financial results, underscoring its position as a global powerhouse in biomanufacturing and biopharma services.

For the quarter ended September 30, 2025, Samsung Biologics reported consolidated revenue of KRW 1,660.2 billion and operating profit of KRW 728.8 billion, representing substantial year-over-year growth driven by Plant 4’s full-scale operations and stable performance across all business units.

“Our third quarter results reflect the solid foundation we have built through operational excellence and disciplined execution,” said John Rim, CEO and President of Samsung Biologics. “We continue to prioritize standardization and scalability across our global network under our ExellenS™ manufacturing framework, delivering speed, reliability, and predictable outcomes our partners can count on. As the industry evolves, our commitment remains clear—to create sustained value for clients by ensuring that every product we manufacture contributes to advancing patient health worldwide.”

Standalone revenue reached KRW 1,257.5 billion, supported by consistent capacity utilization and project execution across all facilities. The company reaffirmed its annual growth guidance, signaling continued strong client demand for large-scale biologics manufacturing and end-to-end CDMO services.

Global Partnerships and Expanding Contract Portfolio

During Q3 2025, Samsung Biologics secured multiple new manufacturing and development contracts with major global pharmaceutical companies. Its cumulative contract volume now exceeds USD 20 billion, reflecting the continued confidence of biopharma partners in its high-quality, large-scale biologics manufacturing capabilities.

The company’s partnerships span a diverse range of biologic modalities, including monoclonal antibodies, bispecifics, and emerging therapeutic platforms. Samsung Biologics’ integrated services—spanning development, fill-finish, and commercial manufacturing—position it as a preferred CDMO partner for global drug developers aiming to accelerate speed-to-market.

Strategic Spin-Off to Strengthen Pure-Play CDMO Focus

Samsung Biologics also confirmed that its planned spin-off of the CDMO business from its subsidiary is on track for completion by November 2025. This strategic separation aims to provide each business with a clear strategic direction and enhanced operational agility.

The restructuring will allow Samsung Biologics to operate as a pure-play CDMO, focused exclusively on biopharmaceutical development and manufacturing. This focused structure is expected to enhance efficiency, strengthen client satisfaction, and drive long-term competitiveness in the global CDMO market.

ExellenS™: A Next-Generation Manufacturing Framework

A key milestone this quarter was the introduction of ExellenS™, Samsung Biologics’ proprietary optimized manufacturing framework designed to standardize operations and accelerate production timelines.

Built on the principles of equivalency, standardization, and speed, ExellenS™ integrates common design, equipment, and processes across all Samsung Biologics facilities. This enables flexible project transitions, ensures consistent product quality, and significantly reduces time-to-market for clients.

The framework reinforces Samsung Biologics’ mission to deliver speed, reliability, and scalability—critical factors for biopharma partners navigating today’s dynamic therapeutic landscape.

Sustainability and ESG Leadership

In Q3 2025, Samsung Biologics strengthened its environmental, social, and governance (ESG) initiatives, reinforcing its role as a sustainability leader in global healthcare manufacturing.

The company implemented a Product Carbon Footprint (PCF) measurement system to monitor and manage emissions across its manufacturing operations and supply chains. As a key member of the Sustainable Markets Initiative’s Health Systems Task Force, Samsung Biologics continues to align its operations with global decarbonization goals.

Through partnerships with suppliers and clients, the company promotes collective climate action, advocating for eco-friendly manufacturing, energy efficiency, and responsible resource management. These efforts are part of Samsung Biologics’ commitment to achieve carbon neutrality and contribute to a more resilient and sustainable healthcare ecosystem.

Outlook for FY2025 and Beyond

With steady client demand, strong operational performance, and upcoming strategic milestones, Samsung Biologics remains on track to meet its full-year 2025 growth targets. The completion of the CDMO spin-off, combined with the rollout of the ExellenS™ framework, will further enhance its ability to deliver end-to-end solutions to global biopharma innovators.

The company’s focus on innovation, reliability, and sustainability continues to differentiate it in a rapidly expanding CDMO market expected to surpass USD 30 billion globally in the next few years.

Under the leadership of CEO John Rim, Samsung Biologics stands at the forefront of global biomanufacturing excellence, combining scale, technological innovation, and ESG stewardship to support the future of biologic therapeutics.

Read More